Venture activity surged as private biotech companies secured roughly $2 billion in a concentrated fundraising week ahead of major industry conferences. Multiple startups closed megaround financings, signaling robust venture appetite for early‑stage platforms and clinical assets despite mixed public markets. The flurry reflects concentrated investor interest in select modalities — including AI‑drug discovery, radiopharma, obesity and cell‑therapy enablement — and sets the tone for deal flow at upcoming investor gatherings.